Central Nervous System Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease, Drug Class, Distribution Channel, and Region

Description

List of Tables

The global central nervous system therapeutics market size is expected to reach USD 381.27 billion by 2034, according to a new study by Polaris Market Research. The report "Central Nervous System Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Disease, Drug Class, Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The central nervous system (CNS) therapeutics market encompasses drugs and treatments for neurological disorders like Alzheimer's, Parkinson's, epilepsy, and depression, focusing on improving brain and spinal cord health and function.

The central nervous system (CNS) therapeutics market is expanding due to the growing incidence of CNS cancers, including brain tumors, gliomas, and other types. The increasing number of diagnoses is driving demand for effective treatments. For example, the American Brain Tumor Association reports that 90,000 people in the US are diagnosed with a primary brain tumor each year, reflecting a rising trend in cases. Additionally, the aging population is contributing to the increase in CNS cancer cases, as older adults are more vulnerable to cancer-causing radiation.

The central nervous system (CNS) therapeutics market growth is being driven by increased government spending on healthcare. Both governments and private sectors are investing more in healthcare, which has led to a stronger focus on developing effective treatments for CNS disorders such as depression, anxiety, and Alzheimer's disease. For example, healthcare expenditure in 2021 accounted for 10.3% of total GDP, according to the World Bank Group. This financial support has fostered research and innovation, resulting in the introduction of cost-effective therapies.

The central nervous system therapeutics market is growing due to advanced diagnostic technologies that make it easier to identify neurological disorders. These advancements lead to earlier and more accurate diagnoses and lead to an increased demand for effective treatments.

Central Nervous System Therapeutics Market Report Highlights

Based on drug class, the CNS stimulants segment is expected to experience significant growth with a high CAGR in the global market due to the rising prevalence of attention deficit hyperactivity (ADHD) and sleep disorders.

By distribution channel, the hospital pharmacies segment dominated the central nervous system therapeutics market in 2024 due to the rising number of hospital admissions for neurodegenerative diseases, such as Alzheimer's and Parkinson's.

In 2024, North America had the largest revenue share in the central nervous system therapeutics market due to the rising prevalence of Alzheimer's disease.

The central nervous system therapeutics market in India is projected for substantial growth, driven by the growth of the pharmaceutical industry.

A few of the global key market players are Biogen; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; Merck & Co., Inc.; Astra Zeneca; Takeda Pharmaceutical Company Limited; Novartis AG; Teva Pharmaceutical Industries Ltd; Johnson & Johnson, Inc.; and Pfizer Inc.

Polaris market research has segmented the central nervous system therapeutics market report on the basis of disease, drug class, distribution channel, and region:

By Disease Outlook (Revenue - USD Billion, 2020-2034)

§ Neurovascular Diseases
§ CNS Trauma
§ Mental Health
§ Neurodegenerative Diseases
§ Alzheimer's Disease
§ Parkinson's Disease
§ Multiple Sclerosis
§ Huntington's Disease
§ Amyotrophic Lateral Sclerosis
§ Others
§ Infectious Diseases
§ CNS Cancer
§ Others

By Drug Class Outlook (Revenue - USD Billion, 2020-2034)

§ Anesthetics
§ Anticonvulsants
§ Antiemetics
§ CNS Stimulants
§ Pain Relievers
§ Others

By Distribution Channel Outlook (Revenue - USD Billion, 2020-2034)

§ Hospital Pharmacies
§ Retail Pharmacies
§ Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa

Product Code: PM5368

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Central Nervous System Therapeutics Market Insights

4.1. Central Nervous System Therapeutics Market - Market Snapshot
4.2. Central Nervous System Therapeutics Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rising Geriatric Population is Driving Market Growth
  - 4.2.1.2. Increase in Investment in Mental Health is Propelling Market Size
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Regulatory Hurdle
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Central Nervous System Therapeutics Market Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Central Nervous System Therapeutics Market, by Disease

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
5.3. Neurovascular Disease
- 5.3.1. Global Central Nervous System Therapeutics Market, by Neurovascular Disease, by Region, 2020-2034 (USD million)
5.4. CNS Trauma
- 5.4.1. Global Central Nervous System Therapeutics Market, by CNS Trauma, by Region, 2020-2034 (USD million)
5.5. Mental Health
- 5.5.1. Global Central Nervous System Therapeutics Market, by Mental Health, by Region, 2020-2034 (USD million)
5.6. Neurodegenerative Diseases
- 5.6.1. Global Central Nervous System Therapeutics Market, by Neurodegenerative Diseases, by Region, 2020-2034 (USD million)
- 5.6.2. Alzheimer's Disease
  - 5.6.2.1. Global Central Nervous System Therapeutics Market, by Alzheimer's Disease, by Region, 2020-2034 (USD million)
- 5.6.3. Parkinsosn's Disease
  - 5.6.3.1. Global Central Nervous System Therapeutics Market, by Parkinsosn's Disease, by Region, 2020-2034 (USD million)
- 5.6.4. Multiple Sclerosis
  - 5.6.4.1. Global Central Nervous System Therapeutics Market, by Multiple Sclerosis, by Region, 2020-2034 (USD million)
- 5.6.5. Huntington's Disease
  - 5.6.5.1. Global Central Nervous System Therapeutics Market, by Huntington's Disease, by Region, 2020-2034 (USD million)
- 5.6.6. Amytrophic Lateral Sclerosis
  - 5.6.6.1. Global Central Nervous System Therapeutics Market, by Amytrophic Lateral Sclerosis, by Region, 2020-2034 (USD million)
- 5.6.7. Others
  - 5.6.7.1. Global Central Nervous System Therapeutics Market, by Others, by Region, 2020-2034 (USD million)
5.7. Infectious Diseases
- 5.7.1. Global Central Nervous System Therapeutics Market, by Infectious Diseases, by Region, 2020-2034 (USD million)
5.8. CNS Cancer
- 5.8.1. Global Central Nervous System Therapeutics Market, by CNS Cancer, by Region, 2020-2034 (USD million)
5.9. Others
- 5.9.1. Global Central Nervous System Therapeutics Market, by Others, by Region, 2020-2034 (USD million)

6. Global Central Nervous System Therapeutics Market, by Drug Class

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
6.3. Anesthetics
- 6.3.1. Global Central Nervous System Therapeutics Market, by Anesthetics, by Region, 2020-2034 (USD million)
6.4. Anticonvulsants
- 6.4.1. Global Central Nervous System Therapeutics Market, by Anticonvulsants, by Region, 2020-2034 (USD million)
6.5. Antiemetics
- 6.5.1. Global Central Nervous System Therapeutics Market, by Antiemetics, by Region, 2020-2034 (USD million)
6.6. CNS Stimulants
- 6.6.1. Global Central Nervous System Therapeutics Market, by CNS Stimulants, by Region, 2020-2034 (USD million)
6.7. Pain Relievers
- 6.7.1. Global Central Nervous System Therapeutics Market, by Pain Relievers, by Region, 2020-2034 (USD million)
6.8. Others
- 6.8.1. Global Central Nervous System Therapeutics Market, by Others, by Region, 2020-2034 (USD million)

7. Global Central Nervous System Therapeutics Market, by Distribution Channel

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
7.3. Hospital Pharmacies
- 7.3.1. Global Central Nervous System Therapeutics Market, by Hospital Pharmacies, by Region, 2020-2034 (USD million)
7.4. Retail Pharmacies
- 7.4.1. Global Central Nervous System Therapeutics Market, by Retail Pharmacies, by Region, 2020-2034 (USD million)
7.5. Others
- 7.5.1. Global Central Nervous System Therapeutics Market, by Others, by Region, 2020-2034 (USD million)

8. Global Central Nervous System Therapeutics Market, by Geography

8.1. Key Findings
8.2. Introduction
- 8.2.1. Central Nervous System Therapeutics Market Assessment, By Geography, 2020-2034 (USD million)
8.3. Central Nervous System Therapeutics Market - North America
- 8.3.1. North America: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.3.2. North America: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.3.3. North America: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.3.4. Central Nervous System Therapeutics Market - U.S.
  - 8.3.4.1. U.S.: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.3.4.2. U.S.: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.3.4.3. U.S.: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.3.5. Central Nervous System Therapeutics Market - Canada
  - 8.3.5.1. Canada: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.3.5.2. Canada: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.3.5.3. Canada: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
8.4. Central Nervous System Therapeutics Market - Europe
- 8.4.1. Europe: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.4.2. Europe: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.4.3. Europe: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.4. Central Nervous System Therapeutics Market - UK
  - 8.4.4.1. UK: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.4.4.2. UK: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.4.4.3. UK: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.5. Central Nervous System Therapeutics Market - France
  - 8.4.5.1. France: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.4.5.2. France: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.4.5.3. France: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.6. Central Nervous System Therapeutics Market - Germany
  - 8.4.6.1. Germany: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.4.6.2. Germany: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.4.6.3. Germany: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.7. Central Nervous System Therapeutics Market - Italy
  - 8.4.7.1. Italy: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.4.7.2. Italy: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.4.7.3. Italy: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.8. Central Nervous System Therapeutics Market - Spain
  - 8.4.8.1. Spain: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.4.8.2. Spain: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.4.8.3. Spain: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.9. Central Nervous System Therapeutics Market - Netherlands
  - 8.4.9.1. Netherlands: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.4.9.2. Netherlands: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.4.9.3. Netherlands: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.10. Central Nervous System Therapeutics Market - Russia
  - 8.4.10.1. Russia: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.4.10.2. Russia: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.4.10.3. Russia: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.4.11. Central Nervous System Therapeutics Market - Rest of Europe
  - 8.4.11.1. Rest of Europe: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.4.11.2. Rest of Europe: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.4.11.3. Rest of Europe: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
8.5. Central Nervous System Therapeutics Market - Asia Pacific
- 8.5.1. Asia Pacific: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.5.2. Asia Pacific: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.5.3. Asia Pacific: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.4. Central Nervous System Therapeutics Market - China
  - 8.5.4.1. China: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.5.4.2. China: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.5.4.3. China: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.5. Central Nervous System Therapeutics Market - India
  - 8.5.5.1. India: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.5.5.2. India: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.5.5.3. India: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.6. Central Nervous System Therapeutics Market - Malaysia
  - 8.5.6.1. Malaysia: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.5.6.2. Malaysia: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.5.6.3. Malaysia: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.7. Central Nervous System Therapeutics Market - Japan
  - 8.5.7.1. Japan: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.5.7.2. Japan: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.5.7.3. Japan: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.8. Central Nervous System Therapeutics Market - Indonesia
  - 8.5.8.1. Indonesia: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.5.8.2. Indonesia: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.5.8.3. Indonesia: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.9. Central Nervous System Therapeutics Market - South Korea
  - 8.5.9.1. South Korea: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.5.9.2. South Korea: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.5.9.3. South Korea: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.10. Central Nervous System Therapeutics Market - Australia
  - 8.5.10.1. Australia: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.5.10.2. Australia: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.5.10.3. Australia: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.5.11. Central Nervous System Therapeutics Market - Rest of Asia Pacific
  - 8.5.11.1. Rest of Asia Pacific: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.5.11.2. Rest of Asia Pacific: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.5.11.3. Rest of Asia Pacific: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
8.6. Central Nervous System Therapeutics Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.6.2. Middle East & Africa: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.6.3. Middle East & Africa: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.6.4. Central Nervous System Therapeutics Market - Saudi Arabia
  - 8.6.4.1. Saudi Arabia: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.6.4.2. Saudi Arabia: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.6.4.3. Saudi Arabia: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.6.5. Central Nervous System Therapeutics Market - UAE
  - 8.6.5.1. UAE: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.6.5.2. UAE: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.6.5.3. UAE: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.6.6. Central Nervous System Therapeutics Market - Israel
  - 8.6.6.1. Israel: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.6.6.2. Israel: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.6.6.3. Israel: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.6.7. Central Nervous System Therapeutics Market - South Africa
  - 8.6.7.1. South Africa: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.6.7.2. South Africa: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.6.7.3. South Africa: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.6.8. Central Nervous System Therapeutics Market - Rest of Middle East & Africa
  - 8.6.8.1. Rest of Middle East & Africa: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.6.8.2. Rest of Middle East & Africa: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.6.8.3. Rest of Middle East & Africa: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
8.7. Central Nervous System Therapeutics Market - Latin America
- 8.7.1. Latin America: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
- 8.7.2. Latin America: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
- 8.7.3. Latin America: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.7.4. Central Nervous System Therapeutics Market - Mexico
  - 8.7.4.1. Mexico: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.7.4.2. Mexico: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.7.4.3. Mexico: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.7.5. Central Nervous System Therapeutics Market - Brazil
  - 8.7.5.1. Brazil: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.7.5.2. Brazil: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.7.5.3. Brazil: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.7.6. Central Nervous System Therapeutics Market - Argentina
  - 8.7.6.1. Argentina: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.7.6.2. Argentina: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.7.6.3. Argentina: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)
- 8.7.7. Central Nervous System Therapeutics Market - Rest of Latin America
  - 8.7.7.1. Rest of Latin America: Central Nervous System Therapeutics Market, by Disease, 2020-2034 (USD million)
  - 8.7.7.2. Rest of Latin America: Central Nervous System Therapeutics Market, by Drug Class, 2020-2034 (USD million)
  - 8.7.7.3. Rest of Latin America: Central Nervous System Therapeutics Market, by Distribution Channel, 2020-2034 (USD million)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. Biogen
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. Otsuka Pharmaceutical Co., Ltd.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Eli Lilly and Company
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. Merck & Co., Inc.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. Astra Zeneca
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Takeda Pharmaceutical Company Limited
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. Novartis AG
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. Teva Pharmaceutical Industries Ltd
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. Johnson & Johnson, Inc.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. Pfizer Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development